Zacks Investment Research
06 Aug 2026, 15:51 UTC · 1h ago
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Aug 2026, 15:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ADMA Biologics' gross margin expanded significantly to 69% from 55% year-over-year. — Substantial margin expansion indicates improved operational efficiency and pricing power, which is strongly positive for valuation.
+0.60Asceniv revenues grew 23.5% year-over-year to $102.9 million, driven by strengthening utilization and new patient starts. — Growth in the company's principal product demonstrates successful market penetration despite competitive pressures.
+0.50Bivigam revenues plummeted 48.5% year-over-year to $19.4 million due to aggressive discounting and competitive pricing. — A sharp decline in a key product line highlights vulnerability to competition and pricing wars in the standard immune globulin market.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
ADMA reported Q2 2026 earnings of 16 cents per share, meeting consensus estimates, while revenues of $124.4 million slightly missed the $126.0 million estimate. — Meeting EPS but slightly missing revenue is generally viewed as a neutral result by the market.
+0.00Which stocks this story touches
Reported earnings matching estimates and year-over-year growth, though revenue slightly missed expectations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
25m ago
